Speaking In New York, The Minister Of Health Calls Domestic Pharmaceutical Industry A Global Health Power
JAKARTA - Health Minister Budi Gunadi Sadikin said strengthening the pharmaceutical industry at the domestic level is a better global health architecture base.
"Indonesia's efforts at the G20 are aimed at building a more resilient Indonesian health security system, including by increasing better domestic capacity to produce various vaccines, drugs and diagnostic tools," said Budi Gunadi Sadikin in a written statement received in Jakarta, Saturday, September 24.
According to Budi, efforts to strengthen the global health architecture also include utilizing collaborative networks for manufacturing collaboration and research centers for vaccine development, drugs and diagnostic tools.
Budi made this statement when he was one of the speakers at the World Economic Forum (WEF) meeting regarding the Distributed Vaccine Manufacturing Collaborative in New York, Wednesday (21/9).
The meeting was attended by representatives of the World Economic Forum Members and the private industry including the global vaccine industry, including the World Trade Organization (WTO), and the Joint United Nations Programme on HIV and AIDS (UNAIDS).
Strengthening the health industry and utilizing cooperative networks for manufacturing is one of the achievements of the G20 presidency series in the health sector.
The Third Meeting of the Health Working Group (HWG) resulted in an agreement to strengthen regulations in supporting the development of global manufacturing centers.
According to Budi, global research and manufacturing regulations are one of the important things that need to be realized so that all countries are ready to face the pandemic in the future.
G20 member countries are encouraged to issue international organizational rules to improve research and manufacturing capabilities.
Some of the potential collaborations that have been identified at the G20 meeting include global biomanufacturing training centers, collaborative research efforts, data sharing mechanisms, public-private partnerships, research and manufacturing ecosystems.
This is also in line with the health transformation of the third pillar of the transformation of the health resilience system.
According to Budi, the pillar launched a future strategy on vaccine certainty and readiness, diagnostics and therapeutics can be produced domestically.
The strategy is carried out by developing research centers and utilizing cooperation between southern hemisphere countries, so that at least 50 targets can be produced domestically from upstream to downstream.